Optimizing Anti-EGFR Therapy in Colorectal Cancer

Clin Cancer Res. 2015 Dec 15;21(24):5415-6. doi: 10.1158/1078-0432.CCR-15-1768. Epub 2015 Oct 13.

Abstract

Treatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. Clin Cancer Res; 21(24); 5415-6. ©2015 AACR.See related article by Peeters et al., p. 5469.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Cetuximab
  • Colorectal Neoplasms / genetics
  • ErbB Receptors / genetics*
  • Humans
  • Mutation
  • Proto-Oncogene Proteins / genetics
  • ras Proteins / genetics*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Proto-Oncogene Proteins
  • ErbB Receptors
  • ras Proteins
  • Cetuximab